About: Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19
Creator	Mulvey, J Laurence, J Seshadri, M
Source	Elsevier; Medline; PMC
abstract	Respiratory failure and acute kidney injury (AKI) are associated with high mortality in SARS-CoV-2-associated Coronavirus disease 2019 (COVID-19). These manifestations are linked to a hypercoaguable, pro-inflammatory state with persistent, systemic complement activation. Three critical COVID-19 patients recalcitrant to multiple interventions had skin biopsies documenting deposition of the terminal complement component C5b-9, the lectin complement pathway enzyme MASP2, and C4d in microvascular endothelium. Administration of anti-C5 monoclonal antibody eculizumab led to a marked decline in D-dimers and neutrophil counts in all three cases, and normalization of liver functions and creatinine in two. One patient with severe heart failure and AKI had a complete remission. The other two individuals had partial remissions, one with resolution of his AKI but ultimately succumbing to respiratory failure, and another with a significant decline in FiO(2) requirements, but persistent renal failure. In conclusion, anti-complement therapy may be beneficial in at least some patients with critical COVID-19.
has issue date	2020-08-06(xsd:dateTime)
bibo:doi	10.1016/j.clim.2020.108555
bibo:pmid	32771488
has license	no-cc
sha1sum (hex)	4b166e095e40c4d3a618d678b66117a312c8861d
schema:url	https://doi.org/10.1016/j.clim.2020.108555
resource representing a document's title	Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19
has PubMed Central identifier	PMC7410014
has PubMed identifier	32771488
schema:publication	Clin Immunol
resource representing a document's body	covid:4b166e095e40c4d3a618d678b66117a312c8861d#body_text
is schema:about of	named entity 'partial' named entity 'remission' named entity 'functions' named entity 'AKI' named entity 'mortality' named entity 'C4D' named entity 'PARTIAL' named entity 'ADMINISTRATION' named entity 'AKI' named entity 'JOURNAL ' named entity 'COMPLETE REMISSION' covid:arg/4b166e095e40c4d3a618d678b66117a312c8861d named entity 'respiratory failure' named entity 'lectin' named entity 'severe' named entity 'resolution' named entity 'complement' named entity 'skin biopsies' named entity 'COVID' named entity 'AKI' named entity 'Coronavirus disease 2019' named entity 'neutrophil' named entity 'C5b' named entity 'complement C5' named entity 'patients' named entity 'receptor' named entity 'lactate dehydrogenase' named entity 'epitope' named entity 'remdesivir' named entity 'D-dimer' named entity 'C5a' named entity 'cyclic peptide' named entity 'COVID' named entity 'aspartate transaminase' named entity 'C4d' named entity 'COVID' named entity 'abscesses' named entity 'complete response' named entity 'P. aeruginosa' named entity 'autoimmune disorders' named entity 'platelets' named entity 'AKI' named entity 'lung' named entity 'normal range' named entity 'serum creatinine' named entity 'Candida albicans' named entity 'mice' named entity 'D-dimer' named entity 'CRP' named entity 'nasopharyngeal' named entity 'intensive care unit' named entity 'Case reports' named entity 'intravenously' named entity 'inflammatory state' named entity 'eculizumab' named entity 'acute kidney injury' named entity 'lectin' named entity 'COVID-19' named entity 'comorbidities' named entity 'eculizumab' named entity 'COVID' named entity 'complement activation' named entity 'proinflammatory cytokines' named entity 'DAB' named entity 'formalin-fixed' named entity 'lung' named entity 'dimers' named entity 'pro-inflammatory cytokines' named entity 'ANC' named entity 'cutaneous' named entity 'C4d' named entity 'LDH' named entity 'inflammatory cytokine' named entity 'eculizumab' named entity 'steroids' named entity 'Complement' named entity 'complement activation' named entity 'humanized monoclonal antibody' named entity 'ANC'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software